Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism

NCT07245927 · clinicaltrials.gov ↗

RECRUITING

Status

20000

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Embolism Acute Massive

Interventions

DRUG: Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin®

Sponsor

Supergene, LLC

Collaborators

[object Object]